NICE recommends use of Farydak® for myeloma patients

The National Institute for Health and Care Excellence (NICE) has recommended the use of Farydak (panobinostat) as a treatment for relapsed and/or refractory myeloma patients who have received at least two previous lines of treatment including Velcade® (bortezomib) and an immunomodulatory drug. This comes after an initial negative guidance issued in September which has now…

Details